The standard post-laser instruction sheet I see handed to patients reads something like: gentle cleanser, occlusive moisturizer, broad-spectrum SPF 30+, no actives for 7-10 days. It’s the same sheet whether the patient is Fitzpatrick II or VI. For Fitzpatrick II patients it’s adequate. For Fitzpatrick V-VI patients it’s the leading cause of treatment-induced hyperpigmentation in cosmetic dermatology.
The asymmetry isn’t about the laser. It’s about what happens in melanocytes after any inflammatory insult in darker skin tones. The therapeutic window when PIH can be prevented extends out to roughly 90 days post-procedure, not 14. The pre-treatment priming that meaningfully reduces PIH risk isn’t standard practice in many clinics. And the actives most patients are told to avoid for “10 days” are exactly the ones that should be reintroduced in week 3 to suppress the melanocyte activation that’s still happening.
I’ll walk through the timeline, the priming, and the lasers that are safer in SoC versus the ones that aren’t.
Why the post-laser window is different for darker skin
Every laser modality used in cosmetic dermatology produces controlled inflammation as part of its therapeutic mechanism. Inflammation is the trigger for the wound-healing cascade, and the wound-healing cascade is where most of the cosmetic benefit comes from — collagen remodeling, pigment cell turnover, vascular reorganization.
In Fitzpatrick I-III skin, that inflammation resolves over 7-14 days. The melanocyte activation that accompanies inflammation is brief and produces minimal visible pigment. In Fitzpatrick IV-VI skin, the same inflammation activates a parallel pathway: sustained α-MSH signaling, PAR-2 mediated melanosome transfer, and an inflammatory infiltrate that can persist subclinically for 8-12 weeks. The visible inflammation resolves at the same 7-14 day timeline. The pigmentary consequence does not.
Alexis and colleagues (Semin Cutan Med Surg 2013) reviewed the data on laser-induced PIH in SoC across modalities. The pattern is consistent: PIH risk extends 4-6 times longer than the visible inflammation, and the window for prevention is much wider than for treatment.
The 90-day melanocyte hyperactivity window
The clinical model I work from: post-procedure melanocyte activation in Fitzpatrick IV-VI skin extends approximately 90 days, with peak hyperactivity in days 14-45. Visible PIH typically appears in days 21-60 — well past the point when most patients have stopped any post-procedure protocol.
This timing has two implications.
First, sun protection that’s “ramped down” after the visible inflammation resolves leaves the highest-risk period unprotected. The PIH that appears at day 35 is often the consequence of unprotected UV exposure on days 14-35, when the patient thought they were “done with recovery.”
Second, the protocols most clinics use are designed around the visible-inflammation timeline. They prevent acute complications and miss the subacute pigmentary ones.
Pre-treatment priming (4 weeks of suppression before procedure)
The single highest-leverage intervention isn’t post-procedure. It’s the 4-week pre-treatment window.
The protocol most evidenced in dermatology literature: hydroquinone 4% nightly for 4 weeks before procedure, sometimes combined with low-potency topical corticosteroid for the final week. The hydroquinone suppresses melanocyte activity at baseline, so the post-procedure inflammation has less melanocyte capacity to recruit. Topical tranexamic acid 3% is a hydroquinone alternative for patients with intolerance or regulatory access issues.
Pre-treatment priming reduces PIH incidence in SoC cohorts by roughly 30-50% across studies that have measured it. It is the most cost-effective single intervention in laser dermatology for darker skin tones, and many clinics skip it.
If you’re scheduling a laser procedure in Fitzpatrick V-VI skin, the question “what are you doing for the 4 weeks before?” is more clinically important than the question “what are you doing for the 14 days after?”
Days 0-7: the inflammation control window
The standard protocol works here: gentle non-foaming cleanser, ceramide-forward occlusive moisturizer (Vanicream, La Roche-Posay Cicaplast, Aquaphor), mineral SPF every two hours during waking hours. No actives — no retinoids, no AHA/BHA, no vitamin C.
The departure from standard: aggressive visible-light protection. Iron oxide-containing tinted mineral sunscreens (EltaMD UV Daily Tinted, La Roche-Posay Anthelios Mineral Tinted, Avene Mineral Tinted) reduce visible-light penetration in addition to UV. Visible light is a significant contributor to melasma and PIH in SoC and is not blocked by standard non-tinted mineral SPF.
Days 0-7 should also include scrupulous heat avoidance. Heat — hot showers, intense workouts, saunas, cooking near open flames — drives independent melanocyte activation through different signaling pathways than UV. Patients who maintain their workout routine post-procedure often develop PIH that’s misattributed to inadequate sun protection.
Days 7-30: re-pigmentation surveillance
Active PIH typically appears in this window. The protocol shifts from inflammation control to early PIH suppression.
Day 14: reintroduce niacinamide 4% AM serum. The mechanism is melanosome transfer inhibition, which is exactly the pathway that’s most active in post-procedure SoC skin.
Day 21: if the laser was non-ablative and surface integrity is intact, reintroduce kojic acid 1-2% or alpha-arbutin 2% PM. These provide tyrosinase inhibition during the melanocyte hyperactivity peak. Skip this step if any open lesions or scabbing remains.
Day 28: photograph the treated area in standardized lighting. Compare against the day 0 baseline. Any visible pigment difference at day 28 indicates PIH is developing — pivot to the days 30-90 protocol.
Days 30-90: PIH prevention vs reactive treatment
If no PIH has developed at day 28, maintain the niacinamide + tyrosinase inhibitor combination through day 90, then ramp down.
If PIH has developed, the protocol pivots to active treatment: topical tranexamic acid 3% bid, kojic acid 2% PM, alpha-arbutin 2% AM, continued visible-light SPF. Expect 6-12 months for fade.
The clinical heuristic: PIH that appears in this window and isn’t aggressively treated within 30 days will take twice as long to fade. Late intervention isn’t equivalent to early intervention.
Lasers safer for SoC, lasers higher-risk
The wavelength and pulse-width characteristics that determine PIH risk:
*Lower-risk in SoC:*
– Q-switched and picosecond Nd:YAG (1064 nm) — deep penetration, low melanin absorption at the wavelength. Standard of care for Hori’s nevus and dermal pigmentation in SoC. Chan and colleagues (Lasers Surg Med 2010) documented the safety profile.
– Long-pulse Nd:YAG (1064 nm) — for hair removal in SoC. Battle and Hobbs (Clin Dermatol 2004) is the foundational reference.
– Picosecond alexandrite (755 nm) at low fluence — for tattoo removal, with careful settings.
– Non-ablative fractional 1550 nm — when energy settings are appropriately reduced.
*Higher-risk in SoC, generally avoided or used with caution:*
– IPL (intense pulsed light) — broad-spectrum, high melanin absorption. PIH rates in Fitzpatrick V-VI exceed 30% in some published series.
– Ablative CO2 (fractional or full-field) — 10,600 nm, deep thermal injury, prolonged inflammation. PIH rates can exceed 40% in dark skin.
– Q-switched ruby (694 nm) — historically used for pigment, now largely replaced by Nd:YAG in SoC because of unacceptable PIH rates.
– 532 nm KTP — high melanin absorption, generally avoided for SoC vascular procedures.
The clinical takeaway: if a clinic is offering you IPL or fractional CO2 for Fitzpatrick V-VI skin, the questions to ask are about their specific PIH rates in your skin type, not the laser’s general safety profile.
The protocol that actually works
Pre-procedure week -4 to -1: hydroquinone 4% nightly (or topical tranexamic acid 3% if hydroquinone unavailable). Daily mineral SPF with iron oxide.
Day 0 (procedure day): gentle cleanser, ceramide occlusive moisturizer, mineral SPF reapplication every two hours, strict heat avoidance.
Days 0-7: maintain. No actives. Photograph at day 0 and day 7.
Days 7-13: continue base protocol. Add visible-light protection if not already in use.
Day 14: reintroduce niacinamide 4% AM serum.
Day 21: reintroduce kojic acid 1-2% or alpha-arbutin 2% PM if surface integrity allows.
Day 28: photograph and compare to day 0. Decide on maintenance vs active PIH treatment.
Days 30-90: maintain melanocyte suppression. If PIH developed, escalate.
Day 90: evaluate for tapering off the prophylactic protocol.
FAQ
*How long does PIH last after laser treatment on dark skin?*
Untreated PIH after laser in Fitzpatrick IV-VI skin typically lasts 6-12 months. With aggressive early intervention starting within 30 days of appearance, fade can be accelerated to 4-8 months. Late intervention (after 60+ days of untreated PIH) extends the timeline significantly.
*What’s the safest laser for Fitzpatrick V skin?*
Q-switched and picosecond Nd:YAG at 1064 nm have the strongest safety record in Fitzpatrick V-VI skin across most cosmetic indications. The wavelength has low melanin absorption, which minimizes thermal injury to epidermal melanocytes.
*Should I use hydroquinone before laser treatment?*
Yes. The 4-week pre-treatment course of hydroquinone 4% (or topical tranexamic acid 3% if hydroquinone is unavailable) reduces PIH incidence in SoC laser cohorts by 30-50% across published studies. This is the single highest-leverage intervention in laser dermatology for darker skin tones.
*What sunscreen should I use after laser if I have darker skin?*
Mineral sunscreen with iron oxide is the standard for SoC post-laser care. Iron oxide blocks visible light in addition to UV, which matters in darker skin tones because visible light contributes meaningfully to PIH and melasma. EltaMD UV Daily Tinted and La Roche-Posay Anthelios Mineral Tinted are widely-used examples.
References
- Alexis AF. Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI. Semin Cutan Med Surg. 2013. PubMed.
- Chan HHL, Shek SY, Yu CS, et al.. Picosecond laser treatment of pigmented disorders. Lasers Surg Med. 2010. PubMed.
- Battle EF Jr, Hobbs LM. Laser-assisted hair removal for darker skin types. Clin Dermatol. 2004. PubMed.
Khabir Uddin is the founder of Elelaf Journal. This article is editorial, not medical advice. Laser procedures in SoC require a clinician experienced specifically with Fitzpatrick IV-VI dermatology. Ask about their PIH rates in your skin type before consenting.